Monitor the company's cash runway and progress of ALN1003 development. The small raise suggests limited near-term capital needs but underscores the pre-revenue, early-stage nature of the business. Any pipeline setbacks could accelerate dilution risk.
Price Chart
Executive Summary
Alaunos Therapeutics announced a registered direct offering of ~767K shares (common + pre-funded warrants) at $1.46/share for ~$1.12M gross proceeds. The small raise signals ongoing cash needs for a pre-revenue biotech advancing an early-stage obesity candidate (ALN1003). Dilution is modest in absolute terms but material given the company's micro-cap status.
Key Financial Metrics
Key Facts
- Registered direct offering of 380,469 common shares and pre-funded warrants for 386,654 shares at $1.46/share
- Aggregate gross proceeds of approximately $1,120,000
- Priced at-the-market under Nasdaq rules
- Expected to close on or about September 21, 2026
- Net proceeds primarily for general working capital and corporate purposes
- Dawson James Securities acting as sole placement agent
- Offered under effective shelf registration statement on Form S-3 (File No. 333-289748)
Financial Impact
~$1.12M gross proceeds; dilution of ~767K shares (common + pre-funded warrants) against an undisclosed share count
Risk Factors
- Pre-revenue biotech with early-stage obesity candidate; no approved products or revenue
- Small raise may not provide sufficient runway for clinical development
- Dilution from pre-funded warrants could pressure stock price
- Micro-cap stock with limited liquidity and high volatility
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3364715 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 4d ago | 8-K | $2.13 | awaiting T+20 | awaiting T+20 | $2.06 (−3.29%) |
Oct 21, 2026 6d ago | 8-K | $3.04 | awaiting T+20 | awaiting T+20 | $2.06 (−32.24%) |
Oct 15, 2026 12d ago | SC 13D/A | $2.63 | awaiting T+20 | awaiting T+20 | $2.06 (−21.67%) |
Oct 15, 2026 12d ago | SC 13D | $2.63 | awaiting T+20 | awaiting T+20 | $2.06 (−21.67%) |
Oct 13, 2026 14d ago | Press Release | $3.03 | awaiting T+20 | awaiting T+20 | $2.06 (−32.01%) |
Oct 13, 2026 14d ago | 8-K | $3.03 | awaiting T+20 | awaiting T+20 | $2.06 (−32.01%) |
Oct 9, 2026 18d ago | 8-K | $1.05 | awaiting T+20 | awaiting T+20 | $2.06 (−96.19%) |
Sep 18, 2026 5w ago | Press Release | $1.20 $2.63 | ▼ −119.17% | ▼ −118.96% | $2.06 (−71.67%) |
Sep 16, 2026 5w ago | 8-K | $1.60 $2.18 | ▲ +36.25% | ▲ +34.79% | $2.06 (+28.75%) |
Jun 29, 2026 17w ago | 8-K | $2.37 $1.94 | ▼ −18.14% | ▼ −17.86% | $2.06 (−13.08%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers